Literature DB >> 18041590

Molecular genetic events in gastrointestinal and pancreatic neuroendocrine tumors.

Irina A Lubensky1, Zhengping Zhuang.   

Abstract

Gastrointestinal and pancreatic neuroendocrine tumors originate from the cells of the diffuse endocrine system. Their molecular genetic mechanism of development and progression is complex and remains largely unknown, and they are different in genetic composition from the gastrointestinal epithelial tumors. The current literature suggests that multiple genes are involved in their tumorigenesis with significant differences for tumors of different embryological derivatives: foregut, midgut and hindgut. The MEN1 gene is involved in initiation of 33% of foregut gastrointestinal neuroendocrine tumors. 18q defects are present almost exclusively in mid/hindgut neuroendocrine tumors. X-chromosome markers are associated with malignant behavior in foregut tumors only. Analysis of poorly differentiated neuroendocrine carcinomas of any site demonstrates high chromosomal instability and frequent p53 alterations similar to other poorly differentiated carcinomas. Several factors played a limiting role in the molecular studies published to date: the tumors are rare and heterogeneous, it is difficult to predict their behavior and prognosis, and several different tumor classifications are used by the investigators in the studies. Future studies need to evaluate molecular genetic composition of large series of gastrointestinal and pancreatic neuroendocrine tumors of each specific tumor type. Understanding of specific genetic alterations characteristic for gastrointestinal and pancreatic neuroendocrine tumors might lead to their improved diagnosis, morphologic and molecular characterization and treatment.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18041590     DOI: 10.1007/s12022-007-9007-x

Source DB:  PubMed          Journal:  Endocr Pathol        ISSN: 1046-3976            Impact factor:   4.056


  64 in total

1.  Deletion at 3p25.3-p23 is frequently encountered in endocrine pancreatic tumours and is associated with metastatic progression.

Authors:  A Barghorn; P Komminoth; D Bachmann; K Rütimann; P Saremaslani; S Muletta-Feurer; A Perren; J Roth; P U Heitz; E J Speel
Journal:  J Pathol       Date:  2001-08       Impact factor: 7.996

2.  Genetic differences in endocrine pancreatic tumor subtypes detected by comparative genomic hybridization.

Authors:  E J Speel; J Richter; H Moch; C Egenter; P Saremaslani; K Rütimann; J Zhao; A Barghorn; J Roth; P U Heitz; P Komminoth
Journal:  Am J Pathol       Date:  1999-12       Impact factor: 4.307

3.  Deletion mapping of endocrine tumors localizes a second tumor suppressor gene on chromosome band 11q13.

Authors:  R Chakrabarti; E S Srivatsan; T F Wood; P J Eubanks; S A Ebrahimi; R A Gatti; E Passaro; M P Sawicki
Journal:  Genes Chromosomes Cancer       Date:  1998-06       Impact factor: 5.006

4.  Comparative genomic hybridization analysis of sporadic neuroendocrine tumors of the digestive system.

Authors:  B Terris; M Meddeb; A Marchio; G Danglot; J F Fléjou; J Belghiti; P Ruszniewski; A Bernheim
Journal:  Genes Chromosomes Cancer       Date:  1998-05       Impact factor: 5.006

5.  Aggressive forms of gastric neuroendocrine tumors in multiple endocrine neoplasia type I.

Authors:  C Bordi; A Falchetti; C Azzoni; T D'Adda; G Canavese; A Guariglia; D Santini; P Tomassetti; M L Brandi
Journal:  Am J Surg Pathol       Date:  1997-09       Impact factor: 6.394

6.  Loss of heterozygosity studies at the retinoblastoma and breast cancer susceptibility (BRCA2) loci in pituitary, parathyroid, pancreatic and carcinoid tumours.

Authors:  S H Pearce; D Trump; C Wooding; M N Sheppard; R N Clayton; R V Thakker
Journal:  Clin Endocrinol (Oxf)       Date:  1996-08       Impact factor: 3.478

7.  Putative tumor suppressor loci at 6q22 and 6q23-q24 are involved in the malignant progression of sporadic endocrine pancreatic tumors.

Authors:  A Barghorn; E J Speel; B Farspour; P Saremaslani; S Schmid; A Perren; J Roth; P U Heitz; P Komminoth
Journal:  Am J Pathol       Date:  2001-06       Impact factor: 4.307

8.  Different patterns of 11q allelic losses in digestive endocrine tumors.

Authors:  Tiziana D'adda; Silvia Pizzi; Cinzia Azzoni; Lorena Bottarelli; Pellegrino Crafa; Claudio Pasquali; Carla Davoli; Vito D Corleto; Gianfranco Delle Fave; Cesare Bordi
Journal:  Hum Pathol       Date:  2002-03       Impact factor: 3.466

9.  Multiple genetic alterations in malignant metastatic insulinomas.

Authors:  K Pavelić; R Hrasćan; S Kapitanović; N Karapandza; Z Vranes; M Belicza; B Kruslin; T Cabrijan
Journal:  J Pathol       Date:  1995-12       Impact factor: 7.996

10.  Pancreatic tumours: molecular pathways implicated in ductal cancer are involved in ampullary but not in exocrine nonductal or endocrine tumorigenesis.

Authors:  P S Moore; S Orlandini; G Zamboni; P Capelli; G Rigaud; M Falconi; C Bassi; N R Lemoine; A Scarpa
Journal:  Br J Cancer       Date:  2001-01       Impact factor: 7.640

View more
  8 in total

1.  Zinc finger transcription factor INSM1 interrupts cyclin D1 and CDK4 binding and induces cell cycle arrest.

Authors:  Tao Zhang; Wei-Dong Liu; Nicolle A Saunee; Mary B Breslin; Michael S Lan
Journal:  J Biol Chem       Date:  2009-01-05       Impact factor: 5.157

2.  Stathmin in pancreatic neuroendocrine neoplasms: a marker of proliferation and PI3K signaling.

Authors:  Simon Schimmack; Andrew Taylor; Ben Lawrence; Hubertus Schmitz-Winnenthal; Lars Fischer; Markus W Büchler; Irvin M Modlin; Mark Kidd; Laura H Tang
Journal:  Tumour Biol       Date:  2014-09-30

3.  Localization of sporadic neuroendocrine tumors by gene expression analysis of their metastases.

Authors:  Nicole Posorski; Daniel Kaemmerer; Guenther Ernst; Patricia Grabowski; Dieter Hoersch; Merten Hommann; Ferdinand von Eggeling
Journal:  Clin Exp Metastasis       Date:  2011-06-17       Impact factor: 5.150

4.  The ENETS/WHO grading system for neuroendocrine neoplasms of the gastroenteropancreatic system: a review of the current state, limitations and proposals for modifications.

Authors:  Marcela S Cavalcanti; Mithat Gönen; David S Klimstra
Journal:  Int J Endocr Oncol       Date:  2016-07-14

5.  Molecular pathology of pancreatic neuroendocrine tumors.

Authors:  Mingyi Chen; Michael Van Ness; Yangtong Guo; Jeffrey Gregg
Journal:  J Gastrointest Oncol       Date:  2012-09

6.  Ribociclib and everolimus in well-differentiated foregut neuroendocrine tumors.

Authors:  Nitya Raj; Youyun Zheng; Haley Hauser; Joanne Chou; Johnathan Rafailov; Jad Bou-Ayache; Peter Sawan; Jamie Chaft; Jennifer Chan; Kimberly Perez; Charles Rudin; Laura Tang; Diane Reidy-Lagunes
Journal:  Endocr Relat Cancer       Date:  2021-04       Impact factor: 5.900

7.  Evolving role of the endoscopist in management of gastrointestinal neuroendocrine tumors.

Authors:  Cemal Yazici; Brian R Boulay
Journal:  World J Gastroenterol       Date:  2017-07-21       Impact factor: 5.742

8.  Frequent overexpression of HMGA1 and 2 in gastroenteropancreatic neuroendocrine tumours and its relationship to let-7 downregulation.

Authors:  M M Rahman; Z R Qian; E L Wang; R Sultana; E Kudo; M Nakasono; T Hayashi; S Kakiuchi; T Sano
Journal:  Br J Cancer       Date:  2009-01-20       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.